Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Pilot Protocol to Evaluate the Efficacy of Letermovir for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis

Next Previous
Trial Profile

An Open-label Pilot Protocol to Evaluate the Efficacy of Letermovir for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letermovir (Primary) ; Letermovir (Primary) ; Ciclosporin; Valganciclovir
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use

Most Recent Events

  • 08 Jul 2025 Status changed from active, no longer recruiting to completed.
  • 20 Dec 2024 Status changed from recruiting to active, no longer recruiting.
  • 01 Mar 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top